-Conference Call Scheduled for Thursday, August 2, 2018 at 4:30pm ET-
NEWARK, Calif.--(BUSINESS WIRE)--Jul. 19, 2018--
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing neuromodulators for use in treating aesthetic and therapeutic
conditions, today announced that the Company will release second quarter
2018 financial results on Thursday, August 2, 2018 after the close of
market. Revance will host a corresponding conference call and a live
webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results
and provide a business and pipeline update.
Individuals interested in listening to the conference call may do so by
dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for
international callers and reference conference ID: 3480629; or from the
webcast link in the investor relations section of the company's website
at: www.revance.com.
A replay of the call will be available beginning August 2,
2018 at 4:30pm PT/7:30pm ET to August 3, 2018 at 4:30pm PT/7:30pm ET. To
access the replay, dial (855) 859-2056 or (404) 537-3406 and reference
conference ID: 3480629. The webcast will be available in the investor
relations section on the company's website for 30 days following the
completion of the call.
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company developing
neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, including muscle movement disorders and pain.
The company's lead drug candidate, DaxibotulinumtoxinA for Injection
(RT002), is currently in development for the treatment of glabellar
lines, cervical dystonia and plantar fasciitis, with plans to initiate
studies in upper limb spasticity and chronic migraine. RT002 has the
potential to be the first long-acting neuromodulator. Revance has
developed a proprietary, stabilizing excipient peptide technology
designed to create novel, differentiated therapies. The company has a
comprehensive pipeline based upon its peptide technology, including
injectable and topical formulations of daxibotulinumtoxinA. More
information on Revance may be found at www.revance.com.
"Revance Therapeutics" and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180719005637/en/
Source: Revance Therapeutics, Inc.
INVESTORS
Revance Therapeutics, Inc.:
Jeanie Herbert,
714-325-3584
jherbert@revance.com
or
Burns
McClellan, Inc.:
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com
or
MEDIA
General
Media:
TOGORUN:
Mariann Caprino, 917-242-1087
m.caprino@togorun.com
or
Trade
Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com